|
|
Volumn 33, Issue 2, 1998, Pages 152-158
|
|
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU group trial 30843
a
|
|
Author keywords
Buserelin; Cyproterone acetate; Maximum androgen blockade; Prostate cancer (metastatic)
|
|
Indexed keywords
ANDROGEN;
ANTIANDROGEN;
BUSERELIN;
CYPROTERONE ACETATE;
FLUTAMIDE;
GONADORELIN AGONIST;
GOSERELIN;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DRUG TOXICITY;
HOT FLUSH;
HUMAN;
INHALER;
INTRANASAL DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
MALE;
METASTASIS;
ORCHIECTOMY;
PRIORITY JOURNAL;
PROGNOSIS;
PROSTATE CANCER;
RANDOMIZED CONTROLLED TRIAL;
STATISTICAL ANALYSIS;
SUBCUTANEOUS DRUG ADMINISTRATION;
TREATMENT OUTCOME;
ACID PHOSPHATASE;
ADMINISTRATION, INTRANASAL;
AGED;
ANDROGEN ANTAGONISTS;
ANTINEOPLASTIC AGENTS, HORMONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BUSERELIN;
CARCINOMA;
CAUSE OF DEATH;
CYPROTERONE ACETATE;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
INJECTIONS, SUBCUTANEOUS;
MALE;
MIDDLE AGED;
ORCHIECTOMY;
PAIN MEASUREMENT;
PROPORTIONAL HAZARDS MODELS;
PROSPECTIVE STUDIES;
PROSTATIC NEOPLASMS;
SURVIVAL RATE;
TREATMENT OUTCOME;
|
|
EID: 0031906113
PISSN: 03022838
EISSN: None
Source Type: Journal
DOI: 10.1159/000019547 Document Type: Article |
|
Times cited : (38)
|
|
References (16)
|
